ArticleTranslational vision science & technology2025
Identification of Matrix Metalloproteinase 3 as a Potential Biomarker for Dry Eye Disease.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microenvironment-Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges.Small science · 2026Review
- Article
- Advances in Pharmacotherapy and Physiotherapy for Dry Eye Disease: Molecular Mechanisms and Future Directions-A Narrative Literature Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate matrix metalloproteinase 3 (MMP-3) levels in tears from patients with dry eye disease (DED) and a DED model and analyze the correlations between tear MMP-3 levels and clinical parameters in patients. Methods: A hyperosmotic-induced DED model was used to assess the expression levels of MMPs. For this, 59 patients with DED (59 eyes) and 21 healthy volunteers (21 eyes) were enrolled in a cross-sectional study. Clinical parameters related to dry eye and tear MMP-3 levels were collected and analyzed. After blocking MMP-3, the DED-related phenotype was measured to evaluate the role of MMP-3 in the DED model. Results: MMP-3 mRNA expression was significantly increased in the DED model in vitro (P = 0.003), and tear MMP-3 levels were significantly elevated in patients with DED (P < 0.001). Moreover, tear MMP-3 levels were positively correlated with the corneal fluorescence staining (CFS) score (P < 0.001) and disease duration (P < 0.001) in patients with DED. A receiver operating characteristic curve analysis revealed a cutoff value of 41.014 ng/mL for the diagnosis of DED, with a sensitivity of 79.7%, a specificity of 85.7%, and an area under the curve of 0.848 (P < 0.001). In the DED model, MMP-3 inhibition significantly alleviated cell apoptosis and inflammation, as well as increased cell viability. Conclusions: MMP-3 levels were significantly elevated in both the DED model and in the tears of patients with DED. Tear MMP-3 levels correlated with the CFS score and may likely serve as a biomarker for DED. The inhibition of MMP-3 expression attenuated DED-induced cell apoptosis, increased cell viability, and reduced inflammation in vitro. Translational Relevance: Tear MMP-3 levels were closely associated with the CFS score of patients with DED, and the inhibition of MMP-3 alleviated the DED-related phenotype in vitro, thereby suggesting that MMP-3 is a potential biomarker for DED diagnosis and could aid in the development of therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.